Newsoara Biopharma Signs a Licensing Agreement with Zenith Epigenetics for its ZEN-3694

Newsoara Biopharma Signs a Licensing Agreement with Zenith Epigenetics for its ZEN-3694Newsoara Biopharma Signs a Licensing Agreement with Zenith Epigenetics for its ZEN-3694

Shots:

  • Zenith Epigenetics will receive $15M as up front and development milestones, ~$63M commercial milestones and up to 6% royalties on sales in the licensed territories which may reduce to 4% based on certain sales milestones are achieved in the territories
  • Newsoara to get rights to develop, commercialize & distribute Zenith’s ZEN-3694 for all indication in China, Hong Kong, Taiwan, and Macau. The license shall expire on a region-by-region basis on the 12th anniversary of the first commercial sale in licensed territories
  • Zenith’s ZEN-3694 is a BET inhibitor, currently being evaluated in P-II study for the treatment of mCRPC & triple-negative breast cancer, administered in combination with other therapies to address resistance and re-sensitize tumors to SOC

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Zenith